News >

Osimertinib Spearheads Progress in EGFR-Mutant NSCLC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Aug 20, 2019

Suresh S. Ramalingam, MD

Suresh S. Ramalingam, MD
Following a frontline approval for patients with EGFR-mutant non–small cell lung cancer (NSCLC), future directions for the third-generation EGFR TKI osimertinib (Tagrisso) include overcoming acquired resistance mechanisms with optimal combination partners, explained Suresh A. Ramalingam, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual School of Nursing Oncology™Sep 28, 20191.5
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Publication Bottom Border
Border Publication